Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF(V600E) mutation

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAF(V600E) metastatic colorectal cancer (mCRC), further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not define...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Discov
Asıl Yazarlar: Hong, David S., Morris, Van K., Osta, Badi El, Sorokin, Alexey V., Janku, Filip, Fu, Siqing, Overman, Michael J., Piha-Paul, Sarina, Subbiah, Vivek, Kee, Bryan, Tsimberidou, Apostolia, Fogelman, David, Bellido, Jorge, Shureiqi, Imad, Huang, Helen, Atkins, Johnique, Tarcic, Gabi, Sommer, Nicolas, Lanman, Richard, Meric-Bernstam, Funda, Kopetz, Scott
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562357/
https://ncbi.nlm.nih.gov/pubmed/27729313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0050
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller